biopsy proven NASH
Type 2 DM
HbA1c :>6.5%
BMI < 45kg/m2
Any anti-diabetic agent except SGLT2 inhibitors, TZDs(thiazolidinediones), DPP4(Dipeptidyl peptidase4) inhibitors and GLP1 RAs(Glucagon-like Peptide 1-Receptor Agonists)

NCT02964715_inc_T1
Condition
NASH
NCT02964715_inc_T2
Procedure
biopsy
NCT02964715_inc_T3
Condition
Type 2 DM
NCT02964715_inc_T4
Measurement
HbA1c
NCT02964715_inc_T5
Value
>6.5%
NCT02964715_inc_T6
Measurement
BMI
NCT02964715_inc_T7
Value
< 45kg/m2
NCT02964715_inc_T8
Drug
anti-diabetic agent
NCT02964715_inc_T9
Negation
except
NCT02964715_inc_T10
Drug
SGLT2 inhibitors
NCT02964715_inc_T11
Drug
TZDs
NCT02964715_inc_T12
Drug
thiazolidinediones
NCT02964715_inc_T13
Drug
(Dip bitors and
NCT02964715_inc_T14
Drug
ptidyl peptidase4) in bitors and
NCT02964715_inc_T15
Drug
GLP1 RAs
NCT02964715_inc_T16
Drug
Glucagon-like Peptide 1-Receptor Agonists
NCT02964715_inc_T17
Scope
SGLT2 inhibitors, TZDs(thiazolidinediones), DPP4(Dipeptidyl peptidase4) inhibitors and GLP1 RAs(Glucagon-like Peptide 1-Receptor Agonists